Nearly all patients with PCOS who received a semaglutide or tirzepatide prescription also had obesity or type 2 diabetestwo conditions for which GLP-1s are FDA-approved and central to managing PCOS-related metabolic risk
Regulatory agencies increasingly recognize the value of surrogate endpoints, adaptive trial designs, and biomarker-driven patient stratification, particularly in areas of high unmet need
Easy-to-follow instructions
There is also possible evidence suggesting a higher risk of depression, anxiety, and, potentially, suicidal thoughts (though some reports show antidepressant potential)
10.1172/jci.insight.89376 47 FrancoR.Rivas-SantistebanR.LilloJ.CampsJ.NavarroG.Reyes-ResinaI
Methionine residues as endogenous antioxidants in proteins